Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Roivant Sciences Ltd(ROIV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ROIV
09/28/2026: ROIV (4-star) is a SELL. SELL for 1 day. Simulated Profits (17.66%). Updated daily EoD!
Roivant Sciences is a commercial-stage biopharmaceutical firm that utilizes a unique 'Vant' subsidiary model to de-risk and develop innovative therapies. The company has a leading position in the dermatology market with its approved product, VTAMA, and has historically delivered strong liquidity through strategic asset divestitures. Its primary growth opportunity lies in expanding its portfolio, particularly with promising immunology candidates. However, the company faces high execution risks, intense competition from large pharmaceutical incumbents, and valuation sensitivity to clinical trial outcomes. This stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to targeted therapeutic breakthroughs and are prepared for the volatility of the biotech sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company focuses on high-upside drug development and platform expansion, which aligns with growth strategies. |
| Momentum investor | Mixed fit | Performance is highly dependent on clinical milestones and news flow, making it suitable for traders when signals are positive. |
| Value investor | Weak fit | The company's reliance on pipeline success makes traditional value metrics like P/E ratios difficult to apply. |
| Dividend investor | Weak fit | Roivant does not pay dividends and reinvests all capital into growth. |
| Low-risk investor | Weak fit | Biotech development carries inherent clinical and regulatory risks that result in high volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results and regulatory decisions often lead to large, sudden movements in share price. |
| Valuation risk | Medium / high | Market valuations are often driven by speculative future cash flows from pipeline assets. |
| Competition risk (immunology/dermatology) | High | Established players have massive resources and entrenched market positions. |
| Business quality | Medium | The 'Vant' model offers operational flexibility but depends heavily on the quality of individual asset selection. |
| Dividend income | Low / none | No dividend is paid or expected in the near term. |
| Execution risk | High | Success depends on the complex execution of drug development, clinical trials, and commercial launch. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 28.35% | Avg. Invested days 39 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 25.86B USD | Price to earnings Ratio - | 1Y Target Price 48.08 |
Price to earnings Ratio - | 1Y Target Price 48.08 | ||
Volume (30-day avg) 9.1M shares | Beta 1.12 | 52 Weeks Range 15.11 - 42.50 | Updated Date 09/27/2026 |
52 Weeks Range 15.11 - 42.50 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Commercial sales of VTAMA cream for psoriasis. | Revenue is primarily generated by selling approved dermatology products. |
| Strategic Deals | Milestone payments and divestitures of Vant companies. | The company often generates significant liquidity through the sale or partnership of its subsidiaries. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22.86B | Price to Sales(TTM) 3433.24 |
Enterprise Value 22.86B | Price to Sales(TTM) 3433.24 | ||
Enterprise Value to Revenue 3035.18 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 722.32M | Shares Floating 582.10M |
Shares Outstanding 722.32M | Shares Floating 582.10M | ||
Percent Insiders 21.44 | Percent Institutions 78.34 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Roivant Sciences Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2021-10-01 | CEO & Director Mr. Matthew Gline | ||
Sector Healthcare | Industry Biotechnology | Full time employees 721 | Website https://roivant.com |
Full time employees 721 | Website https://roivant.com | ||
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.